Harbour BioMed’s immunology strategy strengthens further as the company announces a key leadership appointment. Harbour BioMed is a global biopharmaceutical company that is traded on HKEX under the symbol of 02142. Recently, the organization has appointed Dr. Lloyd Klickstein as the Scientific Advisor for Immunology.
The immunology development at the company will definitely benefit immensely from the international experience that Dr. Klickstein possesses. In addition to that, he is an experienced leader having over 20 years of experience in innovation, translational research, and clinical practice. Currently, he is the Chief Executive Officer of Koslapp Therapeutics. In addition, he is one of the founders of Versanis Bio.
“We are delighted to welcome Dr. Lloyd Klickstein as our Scientific Advisor for Immunology,” said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. “Lloyd brings a unique combination of deep clinical expertise in rheumatology and immunology, a distinguished track record in translational science, and extensive experience in advancing innovative therapeutics from discovery through clinical development. His leadership in identifying and validating novel therapeutic targets, particularly during his tenure at Novartis, will be highly valuable as we continue to strengthen and expand our immunology pipeline. We look forward to working closely with Lloyd to accelerate the development of next-generation antibody therapies and deliver meaningful innovations for patients with immunological diseases.”
Expanding Expertise Across Global Biotech Leadership
Additionally, Dr. Klickstein has had high-profile roles in many reputable biotechnology firms. For example, he was the Chief Innovation Officer of Adicet Bio. Moreover, he was the Chief Scientific Officer at resTORbio, which was the predecessor firm to Adicet Bio. Additionally, he was an independent board member of Blade Therapeutics.
In the early stages of his career, he had more than a decade of experience with Novartis. At Novartis, he headed the New Indications Discovery Unit from within the Novartis Institutes for BioMedical Research. His role entailed the identification and validation of new targets for drug development. Prior to entering the biotech industry, he had been a physician-scientist with the Brigham and Women’s Hospital of Harvard Medical School.
“I am honored to join Harbour BioMed as Scientific Advisor for Immunology at such an exciting stage of the Company’s growth,” said Dr. Lloyd Klickstein. “Harbour BioMed has built a differentiated portfolio employing their proprietary antibody discovery platforms with the potential to address significant unmet needs in immunological diseases. I look forward to working closely with the team to help advance innovative immunology programs, identify promising new therapeutic opportunities, and ultimately bring meaningful treatment options to patients.”
Moreover, Dr. Klickstein expressed strong enthusiasm about joining the company at a key growth stage. He stressed the importance of Harbor BioMed’s unique platforms for discovering antibodies, along with their ability to meet medical requirements. He also mentioned that the company is developing its immunology portfolio through scientific innovations. Finally, the company’s immunology expansion reflects its continued commitment to advancing next-generation antibody therapies. The appointment reinforces its long-term strategy to deliver meaningful innovation in immunological disease treatment worldwide.
Explore HR Tech News for the latest advancements in Human Resources Technologies and insightful updates from industry experts!
News Source: PRNewswire.com
